Kangfang Biological (09926.HK): The for Yidafang (Ivosidenib, PD-1/VEGF) for its third indication has been approved by the National Medical Products Administration, for first-line treatment of SQ-NSCLC.

Zhuhai Securities App reported that Akros Biosciences (09926.HK) announced that its independently developed world-first bispecific antibody Idebenone (Evolsib, PD-1/VEGF) in combination with chemotherapy has been approved by the National Medical Products Administration (NMPA) for a new drug application (sNDA) for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC). This marks the third indication for Evolsib to be approved for marketing.